191 related articles for article (PubMed ID: 37750170)
1. GBP5 Expression Predicted Prognosis of Immune Checkpoint Inhibitors in Small Cell Lung Cancer and Correlated with Tumor Immune Microenvironment.
Tong Q; Li D; Yin Y; Cheng L; Ouyang S
J Inflamm Res; 2023; 16():4153-4164. PubMed ID: 37750170
[TBL] [Abstract][Full Text] [Related]
2. MYCBP2 expression correlated with inflammatory cell infiltration and prognosis immunotherapy in thyroid cancer patients.
Wang G; Miao C; Mo L; Kahlert UD; Wu J; Ou M; Huang R; Feng R; Pang W; Shi W
Front Immunol; 2022; 13():1048503. PubMed ID: 36582246
[TBL] [Abstract][Full Text] [Related]
3. GBP5 Identifies Immuno-Hot Tumors and Predicts the Therapeutic Response to Immunotherapy in NSCLC.
Fan H; Shi Y; Wang H; Li Y; Mei J; Xu J; Liu C
Int J Gen Med; 2023; 16():1757-1769. PubMed ID: 37193249
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Bioinformatics Analysis Identifies Tumor Microenvironment and Immune-related Genes in Small Cell Lung Cancer.
Song Y; Sun Y; Sun T; Tang R
Comb Chem High Throughput Screen; 2020; 23(5):381-391. PubMed ID: 32264809
[TBL] [Abstract][Full Text] [Related]
5. Critical role of guanylate binding protein 5 in tumor immune microenvironment and predictive value of immunotherapy response.
Li X; Song D; Su S; He X; Cao F; Yang C; Li K; Huang S; Li C; Wang C; Zhang A; Pang P; Zheng Y
Front Genet; 2022; 13():984615. PubMed ID: 36246628
[No Abstract] [Full Text] [Related]
6. MMP9 Expression Correlates With Cisplatin Resistance in Small Cell Lung Cancer Patients.
Wu L; Wang X; He X; Li Q; Hua Q; Liu R; Qiu Z
Front Pharmacol; 2022; 13():868203. PubMed ID: 35431936
[No Abstract] [Full Text] [Related]
7. Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.
Yan Y; Wang X; Liu C; Jia J
BMC Pulm Med; 2022 Apr; 22(1):166. PubMed ID: 35484541
[TBL] [Abstract][Full Text] [Related]
8. Advances in immune checkpoint inhibitors therapy for small cell lung cancer.
Li L; Liang Y; Yu M; Zhao L; Mei Q; Yu Y; Wang N; Zhang D; Wang Z; Jia Y; Kong F
Cancer Med; 2023 May; 12(10):11097-11106. PubMed ID: 36880420
[TBL] [Abstract][Full Text] [Related]
9. Analysis of Interleukin-1 Signaling Alterations of Colon Adenocarcinoma Identified Implications for Immunotherapy.
Zhou X; Liu Y; Xiang J; Wang Y; Wang Q; Xia J; Chen Y; Bai Y
Front Immunol; 2021; 12():665002. PubMed ID: 34367132
[TBL] [Abstract][Full Text] [Related]
10. [Therapeutic efficacy analysis of immunotherapy in small cell lung cancer].
Zhong J; Zheng QW; Zhao J; Wang ZP; Wu MN; Zhuo ML; Wang YY; Li JJ; Yang X; Chen HX; An TT
Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):771-776. PubMed ID: 32988161
[No Abstract] [Full Text] [Related]
11. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.
Ricciuti B; Kravets S; Dahlberg SE; Umeton R; Albayrak A; Subegdjo SJ; Johnson BE; Nishino M; Sholl LM; Awad MM
J Immunother Cancer; 2019 Mar; 7(1):87. PubMed ID: 30922388
[TBL] [Abstract][Full Text] [Related]
12. A retrospective real-world experience of immunotherapy in patients with extensive stage small-cell lung cancer.
Qiu G; Wang F; Xie X; Liu T; Zeng C; Chen Z; Zhou M; Deng H; Yang Y; Lin X; Xie Z; Sun G; Zhou C; Liu M
Cancer Med; 2023 Jul; 12(14):14881-14891. PubMed ID: 37462138
[TBL] [Abstract][Full Text] [Related]
13. Galectin-9-based immune risk score model helps to predict relapse in stage I-III small cell lung cancer.
Chen P; Zhang L; Zhang W; Sun C; Wu C; He Y; Zhou C
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33082168
[TBL] [Abstract][Full Text] [Related]
14. CCL5 as a Prognostic Marker for Survival and an Indicator for Immune Checkpoint Therapies in Small Cell Lung Cancer.
Tang Y; Hu Y; Niu Y; Sun L; Guo L
Front Med (Lausanne); 2022; 9():834725. PubMed ID: 35252266
[TBL] [Abstract][Full Text] [Related]
15. Identification and validation of a ferroptosis-related prognostic risk-scoring model and key genes in small cell lung cancer.
Li S; Qiu G; Wu J; Ying J; Deng H; Xie X; Lin X; Xie Z; Qin Y; Wang Y; Ma X; Brcic L; Provencio M; Chen Y; Zhou C; Liu M
Transl Lung Cancer Res; 2022 Jul; 11(7):1380-1393. PubMed ID: 35958330
[TBL] [Abstract][Full Text] [Related]
16. Small cell lung cancer patients treated with immune checkpoint inhibitor: a systematic literature review of treatment efficacy, safety and quality of life.
Korde R; Veluswamy R; Allaire JC; Barnes G
Curr Med Res Opin; 2022 Aug; 38(8):1361-1368. PubMed ID: 35575164
[TBL] [Abstract][Full Text] [Related]
17. Identification of Immune Subtypes and Candidate mRNA Vaccine Antigens in Small Cell Lung Cancer.
Wei Y; Zheng L; Yang X; Luo Y; Yi C; Gou H
Oncologist; 2023 Nov; 28(11):e1052-e1064. PubMed ID: 37399175
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoints OX40 and OX40L in Small-Cell Lung Cancer: Predict Prognosis and Modulate Immune Microenvironment.
Chen P; Wang H; Zhao L; Guo H; Zhang L; Zhang W; Sun C; Zhao S; Li W; Zhu J; Yu J; Wu C; He Y
Front Oncol; 2021; 11():713853. PubMed ID: 34900670
[TBL] [Abstract][Full Text] [Related]
19. Current status and future perspectives of immune checkpoint inhibitors in extensive-stage small cell lung cancer.
Liu X; Xing H; Liu B
Am J Cancer Res; 2022; 12(6):2447-2464. PubMed ID: 35812062
[TBL] [Abstract][Full Text] [Related]
20. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
